H.R. 9599, Drug Discount Program Integrity & Access Expansion. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 9599 · Mixed
What it does
This bill strengthens the 340B drug discount program by tightening eligibility rules for who qualifies as a 'patient,' establishing clear requirements for 'prescribing providers,' and creating robust oversight of contract pharmacies. It also expands the program to allow certain covered entities (federally qualified health centers, critical access hospitals, sole community hospitals) to dispense drugs prescribed by outside providers if they referred the patient, subject to strict documentation and audit requirements.
The analysis names Low-income and uninsured patients at federally qualified health centers, critical access hospitals, — and 1 more group — among the beneficiaries.
The trade-off
The 35% referral-prescription threshold and audit triggers may incentivize covered entities to limit referral-based dispensing to stay below audit thresholds, potentially reducing patient access to the expanded benefit.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Scott Peters. Cosponsored by Carol Miller, Dan Crenshaw, Jake Auchincloss and John Joyce.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.